Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trialsThere are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.{}

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.https://www.cnbc.com/2026/07/23/eli-lilly-will-file-for-approval-of-retatrutide-obesity-drug-in-2027.html